|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||146.60 - 147.41|
|52 Week Range||128.58 - 149.58|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.06%|
When it comes to investing, small-cap stocks beat large caps as the best ETFs to buy. After all, it’ll take a lot of a behemoth like International Business Machines Corp. (NYSE:IBM) to get the ship moving. Which is why small-cap stocks have tacked on an extra 253% in cumulative extra returns over large-cap stocks.
While risk-takers will eschew broader-scoped exchange-traded funds (ETFs) for the glory (and profits) of individual stocks, ETFs are a relevant component of any investing strategy. While the profit potential is greatest with a bet on a single company, the opposite is also true. Over the long run, the law of averages makes choosing the best Vanguard ETFs particularly compelling.
Stocks were mixed as Amgen and Celgene hurt biotechs, and ahead of ahead of Amazon and Alphabet's earnings after the close.
Key U.S. stock indexes sold off Wednesday as earnings reports continued and amid renewed talk about changes to 401(k) contribution limits.
Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.
Acadia Pharmaceuticals' (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.
In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).
Here's how exchange-traded funds work, why they benefit retail investors, and how to pick the right ETFs for your portfolio.
On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.
With arrival of spring comes first-quarter earnings announcements throughout the stock market. Large-cap companies generally report a little earlier, business results are better than 1Q's GDP might imply, and the news so far for both small- and ...
By Roger Nusbaum, AdvisorShares ETF Strategist The title of this post is a play on the bit in the movie Stripes when Bill Murray talks about dogs and cats living together. You probably heard about the niche ETF (naming names is difficult for ...
Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.
U.S. stocks are off to another stellar year. Look below the surface, however, and the rally has had a somewhat unusual flavor. Some of the better performing stocks are in the more defensive industries, such as utilities and health care, while small ...
At the start of each year, I put together a list of predictions gurus make for the upcoming year—sort of a consensus of “sure things.” We keep track of the sure things with a review at the end of each quarter. With March behind us, it’s time for our first review. As is our practice, we give a positive score for a forecast that came true, a negative score for one that was wrong and a zero for one that was basically a tie.
Rewind back to late 2016 and early 2017 and it is easy to find a slew of articles speculating that 2017 would be the year of stock pickers and that active managers would bounce back against passive products, ...
Todd Rosenbluth is director of ETF and mutual fund research at CFRA. While 2017 was supposedly set up as a U.S. stock pickers’ market—with a new president, a Federal Reserve poised to raise rates and expectations of higher stock dispersion creating opportunities to spot winners—it is not looking good so far. Just 31% of large-cap core mutual funds ended the first quarter beating the S&P 500 index’s total return, while 33% of small-cap core funds bested the Russell 2000 Index.